Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881891 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TDP1RAB9ANPC1POLB | |
| SCHEMBL19334011 | 0.82 | CYP1A2 (0.43) | ALDH1A1TDP1RAB9ANPC1POLB | |
| SCHEMBL6296479 | 0.81 | TAAR1 (0.46) | ALDH1A1TDP1RAB9ANPC1KMT2A | |
| SCHEMBL12374111 | 0.81 | SLC1A3 (0.49) | ALDH1A1TDP1RAB9ANPC1POLB | |
| SCHEMBL259982 | 0.78 | SLC1A3 (0.46) | ALDH1A1TDP1RAB9ANPC1POLB | |
| SCHEMBL8075617 | 0.78 | — | — | |
| SCHEMBL11676414 | 0.78 | — | — | |
| SCHEMBL19333974 | 0.77 | CA1 (0.41) | ALDH1A1TDP1RAB9ANPC1CYP1A2 | |
| SCHEMBL28023546 | 0.77 | POLB (0.49) | TDP1RAB9ANPC1POLBCYP1A2 | |
| SCHEMBL13197240 | 0.77 | POLB (0.45) | ALDH1A1POLBCYP1A2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-08 | — | — | US | disclosed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8846023-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | ALDH1A1 1136/4885TDP1 3693/4885RAB9A 1617/4885 |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TDP1 3331/4885RAB9A 2463/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TDP1 3331/4885RAB9A 2463/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TDP1 3331/4885RAB9A 2463/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | ALDH1A1 1236/4885TDP1 3805/4885RAB9A 2683/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | ALDH1A1 1344/4885TDP1 3626/4885RAB9A 2534/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | ALDH1A1 1344/4885TDP1 3626/4885RAB9A 2534/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TDP1 3331/4885RAB9A 2463/4885 |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TDP1 3331/4885RAB9A 2463/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885TDP1 3331/4885RAB9A 2463/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | ALDH1A1 1229/4885TDP1 2606/4885RAB9A 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.